繁體
简体中文
繁體中文
×

Sanofi GCVRZ 深 滬

已收盤 03-26 16:00:00 美东时间

0.8711

0.000

0.00%

华盛通華盛通
立即下載
  • 最 高--
  • 今 開--
  • 成交量 0股
  • 最 低 --
  • 昨 收 0.8711
  • 總市值 1113.52亿
  • 52周最高 0.882
  • 市盈率 靜 --
  • 換手率 0.00%
  • 52周最低 0.43
  • 委 比 0.00%
  • 總股本 1278.30亿
  • 歷史最高 0.882
  • 量 比 0
  • 振 幅 0.00%
  • 歷史最低 0.153
  • 每 手 1
  • 風險率 0.00%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多

  • UPDATE 4-Trump unveils TrumpRx discounted drugs website

    UPDATE 4-Trump unveils TrumpRx discounted drugs website TrumpRx.gov to offer discounted drugs via GoodRx, not direct sales Deals with major drugmakers include Eli Lilly, Novo Nordisk, Merck TrumpRx targets cash-paying consumers without insurance Updates with WH event, website online in paragraph 2,

    02-06 00:24

  • BUZZ-Perspective Therapeutics jumps after $175 mln equity offering

    BUZZ-Perspective Therapeutics jumps after $175 mln equity offering ** Radiation oncology firm Perspective Therapeutics CATX.A shares up 17.3% at $4.44 on Mon after $175 mln follow-on offering ** CATX early Mon announced pricing 46.2 mln shares, including ~6.6 mln pre-funded warrants, at $3.79, in li

    02-02 23:34

  • Sanofi graft-versus-host disease asset Rezurock gains EU approval recommendation

    The European Medicine Association's Committee for Medicinal Products for Human Use has given a positive recommendation for conditional approval to Sanofi's (SNY) chronic graft-versus-host disease trea...

    01-30 21:51

  • FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms

    FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms Changes dateline, adds Eli Lilly details in paragraph 11 Jan 30 (Reuters) - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% tariff on imported branded

    01-30 20:07

  • Regeneron Pharma Q4 adjusted EPS beats estimates on demand for Dupixent, EYLEA

    Regeneron Pharma Q4 adjusted EPS beats estimates on demand for Dupixent, EYLEA Overview Biotechnology firm's Q4 revenue rose 3%, beating analyst expectations Adjusted EPS for Q4 beat analyst expectations Company announced FDA approvals for EYLEA HD and Libtayo Outlook Regeneron expects 2026 GAAP R&D

    01-30 19:42

  • Sanofi Warns Dupixent Is Too Big To Replace As Patent Clock Ticks

    Sanofi SA (NASDAQ: SNY) reported Q4 sales of $13.159B, missing consensus of $13.41B. CEO expects profitable growth to continue over 5 years.

    01-29 20:08

  • UPDATE 3-Sanofi vaccine sales face headwinds from US policy shifts

    UPDATE 3-Sanofi vaccine sales face headwinds from US policy shifts Blockbuster drug Dupixent too big to be mitigated, CFO says Expects continued M&A activity this year CEO sees opportunity for vaccine-focused deals Vaccine sales likely 'slightly negative' this year on US weakness Recasts with CEO co

    01-29 15:11

  • Sanofi Q4 Adj. EPS $0.89 Beats $0.84 Estimate

    Sanofi (NASDAQ:SNY) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $0.84 by 5.95 percent.

    01-29 15:00

  • Sanofi Q4 Sales $13.159B Miss $13.410B Estimate

    Sanofi (NASDAQ:SNY) reported quarterly sales of $13.159 billion which missed the analyst consensus estimate of $13.410 billion by 1.87 percent. This is a 16.71 percent increase over sales of $11.275 billion the same

    01-29 14:39

  • Sanofi targets high single digit sales growth in 2026, plans share buyback

    Sanofi targets high single digit sales growth in 2026, plans share buyback LONDON, Jan 29 (Reuters) - French drugmaker Sanofi SASY.PA said on Thursday it expects sales to grow by a high-single-digit percentage in 2026, banking on strong demand for its blockbuster asthma drug Dupixent and some newer

    01-29 14:30

9:00~次日9:00（交易日），9:00~18:00（非交易日）
客戶端：
關注我們：

© 2026 深圳市時代華盛網絡科技有限公司版權所有 粵ICP備16068286號